Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.
Magnus NilssonMagdalena RhedinRamon HendrickxSusanne BerglundAntonio PirasParmis BlomgranAnders CavallinMia CollinsGöran DahlBilel DekkakTherese EricssonNiklas HagbergAnn Aurell HolmbergAgnes LefflerAnders J LundqvistThomais MarkouJames PinkertonLars RönnblomStacey SiuVanessa TaylorTiiu WennbergDimitrios ZervasArian Dominic John LaurenceSuman MitraMaria G BelvisiMark A BirrellAnnika BordePublished in: Drug design, development and therapy (2022)
AZD0449 and AZD4604 show potential as inhibitors of signaling pathways involved in asthmatic immune responses, with target engagement demonstrated locally in the lung. These findings support the clinical development of AZD0449 and AZD4604 for the treatment of patients with asthma.